INVO Bioscience is a medical devices business based in the US. INVO Bioscience shares (INVO) are listed on the NASDAQ and all prices are listed in US Dollars. INVO Bioscience employs 15 staff and has a trailing 12-month revenue of around $1.2 million.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $1.01 |
|---|---|
| 52-week range | $0.92 - $29.60 |
| 50-day moving average | $2.86 |
| 200-day moving average | $8.64 |
| Wall St. target price | $20.00 |
| PE ratio | 0.0595 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $25.36 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.01 from 2023-09-21
| 1 week (2023-09-15) | -2.88% |
|---|---|
| 1 month (2023-08-23) | -34.42% |
| 3 months (2023-06-23) | 512.12% |
| 6 months (2023-03-23) | 53.73% |
| 1 year (2022-09-23) | -6.22% |
|---|---|
| 2 years (2021-09-23) | -69.21% |
| 3 years (2020-09-23) | 6.4 |
| 5 years (2018-09-21) | 12.7904 |
Valuing INVO Bioscience stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of INVO Bioscience's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
INVO Bioscience's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, INVO Bioscience shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, INVO Bioscience's P/E ratio is best considered in relation to those of others within the medical devices industry or those of similar companies.
| Revenue TTM | $1.2 million |
|---|---|
| Gross profit TTM | $535,273 |
| Return on assets TTM | -92.01% |
| Return on equity TTM | -1224.53% |
| Profit margin | 0% |
| Book value | $-2.06 |
| Market Capitalization | $3.7 million |
TTM: trailing 12 months
We're not expecting INVO Bioscience to pay a dividend over the next 12 months.
You may also wish to consider:
INVO Bioscience's shares were split on a 1:20 basis on 28 July 2023. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your INVO Bioscience shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for INVO Bioscience shares which in turn could have impacted INVO Bioscience's share price.
Over the last 12 months, INVO Bioscience's shares have ranged in value from as little as $0.92 up to $29.598. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while INVO Bioscience's is 1.1773. This would suggest that INVO Bioscience's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
To put INVO Bioscience's beta into context you can compare it against those of similar companies.
INVO Bioscience, Inc. , a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. INVO Bioscience, Inc. was founded in 2007 and is based in Sarasota, Florida. .
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.